Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.
Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by ...
The lawsuit consumes valuable taxpayer-funded resources. YEMASSEE, SOUTH CAROLINA / ACCESS Newswire / March 11, 2025 / Alpha ...
Inovio Pharmaceuticals, AstraZeneca, University of Pennsylvania, HR0011-21-9-0001) for this effort. The views expressed in this press release reflect the views of the authors and do not necessarily ...
MyChesCo on MSN7h
INOVIO Reports Groundbreaking Results in COVID-19 Antibody TrialINOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...
MyChesCo on MSN11h
INOVIO to Announce Q4 and Year-End 2024 Results on March 18, 2025INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback